Chernett Jorey purchased $44K of STIM

Chernett Jorey purchased 14,000 shares of Neuronetics, Inc. (STIM) at $3.16 on 2026-08-14.

Original reporting
SEC EDGAR · Chernett Jorey
Published Aug 17, 2026, 2:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 17, 2026, 2:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$STIM
Bullish
medium confidence
Mentioned
$STIM
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$STIMBullishLow
01

Why it matters

The newest information is the disclosed open-market purchase of 14,000 shares at $3.1600 on 2026-08-14, filed on 2026-08-17.

02

Market read

Traders may treat the insider buy as a small sentiment input, but the article lacks any new fundamental catalyst.

03

What to watch

The filing does not state motivations, timing constraints, or whether the insider already held a large position; traders may discount the trade relative to broader fundamentals.

Relevance 4/10Novelty 4/10Timing: filed 2026-08-17, transaction dated 2026-08-14

Background

This is an SEC Form 4 insider transaction for Neuronetics, Inc. (STIM) by 10% owner Chernett Jorey.

Company-level read

Ticker impact

$STIMBullishMedium confidence
Context

Neuronetics Form 4 shows 10% owner Chernett Jorey bought 14,000 shares at $3.1600 on 2026-08-14 for $44,240.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and typically fades unless followed by additional disclosures.

Evidence & confidence

Form 4 provides a fresh, primary-source transaction, but the article contains no new company-specific operational, financial, or regulatory development beyond the insider trade.

Market effects

No sector-wide signal; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

Insider purchases can be routine or planned; without a 10b5-1 plan and with a small dollar amount, the signal may be weak.

Key entities

  • Neuronetics, Inc.

    Company subject of the Form 4 insider transaction (STIM).

  • Chernett Jorey

    10% owner who purchased 14,000 shares open-market at $3.1600.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$STIMHigh

Why is Neuronetics stock tumbling today?

Neuronetics Inc's stock fell 11.4% in pre-market trading after pricing a $30M share offering at a discount. The company aims to use proceeds to address going concern risks and meet a $15M loan prepayment deadline by November 30, 2026. Despite Q3 revenue growth, these factors drove the decline, with no broader market impact.

$STIMHigh

Neuronetics stock tumbles 10% on stock offering launch

Neuronetics Inc (STIM) shares dropped 10% in after-hours trading after announcing a public stock offering and a credit agreement amendment. The company aims to sell shares with a 30-day option for underwriters to buy 15% more. The amendment reduces revenue covenants if certain conditions are met by November 30, 2026, addressing going concern risks. William Blair, BTIG, and Canaccord Genuity are managing the offering.

$STIMHigh

Neuronetics Inc (STIM) (Q3 2026) Earnings Call Highlights: Revenue Jumps

Neuronetics Inc (STIM) reported Q3 2026 revenue of $42M, up 12.5% YoY, driven by Greenbrook's 20.1% growth. Gross margin expanded to 52.2%, and operating expenses decreased 12.6%, leading to positive adjusted EBITDA of $1.9M. NeuroStar revenue grew only 1.8% YoY, with session revenue declining. Cash balance decreased to $27.9M. Management expects full-year 2026 cash flow to be negative $10M to $12M.

$STIMMed

Neuronetics Q3 Earnings Call Highlights

Neuronetics reported Q3 revenue growth driven by record system sales, with capital and lease units making up over half of sales. The company expects lower treatment-session revenue as it shifts focus to larger customers. Neuronetics anticipates higher growth in 2027 and beyond. It also submitted a 510(k) application for an accelerated TMS protocol and cited a study showing treatment gaps do not reduce effectiveness.